Home/Pipeline/Undisclosed Bispecific Program (e.g., PD-1 x VEGF)

Undisclosed Bispecific Program (e.g., PD-1 x VEGF)

Solid Tumors

Phase 1Trial Now Enrolling

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Trial Now Enrolling

Company

Crescent Biopharma

About Crescent Biopharma

Crescent Biopharma is a San Diego-based public company (NASDAQ: CBIO) founded in 2018 with a mission to build a world-leading oncology firm. It focuses on recent breakthroughs in immuno-oncology and ADC technology to develop transformative therapies for solid tumors. The company is led by a seasoned executive team with deep expertise in drug development and corporate finance, and it is advancing a pipeline designed to work both alone and synergistically.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active